Amarin Informed by FDA That October 16th Advisory Committee Meeting Will Take Place as Scheduled

Amarin Informed by FDA That October 16th Advisory Committee Meeting Will Take
Place as Scheduled

BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that it was notified by the U.S. Food and Drug
Administration (FDA) that the scheduled advisory committee meeting to be held
on October 16, 2013 in connection with the proposed Vascepa^® (icosapent
ethyl) ANCHOR indication will take place as scheduled despite the current
Federal Government lapse in appropriations.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Forward-looking statement

This press release contains a forward-looking statement about whether the FDA
will hold the planned advisory committee meeting in connection with its review
of Amarin's pending Supplemental New Drug Application for Vascepa. This
forward-looking statement is not a promise or guarantee and involves the risk
that the FDA will later decide to delay or cancel the planned advisory
committee meeting. A further list and description the risks and uncertainties
associated with an investment in Amarin can be found in Amarin's filings with
the U.S. Securities and Exchange Commission, including its most recent
Quarterly Report on Form 10-Q. Existing and prospective investors are
cautioned not to place undue reliance on this forward-looking statement, which
speaks only as of the date hereof. Amarin undertakes no obligation to update
or revise the information contained in this press release, whether as a result
of new information, future events or circumstances or otherwise.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and
the public using our company website (www.amarincorp.com), our investor
relations website (http://www.amarincorp.com/investor-splash.html), including
but not limited to investor presentations and investor FAQs, Securities and
Exchange Commissionfilings, press releases, public conference calls and
webcasts. The information that we post on these channels and websites could be
deemed to be material information. As a result, we encourage investors, the
media, and others interested in Amarin to review the information that we post
on these channels, including our investor relations website, on a regular
basis. This list of channels may be updated from time to time on our investor
relations website and may include social media channels. The contents of our
website or these channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933.

CONTACT: Amarin contact information:
         Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.